Induction of immune tolerance in the treatment of rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 7, Issue 5, 2011, Pages 272-281

  Albani, Salvatore ^a   Koffeman, Eva C ^b   Prakken, Berent ^b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CANAKINUMAB; COLLAGEN TYPE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; GLYCOPROTEIN GP 39; GOLIMUMAB; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PROTEIN DNAJP1; RITUXIMAB; RUXOLITINIB; SECUKINUMAB; STEROID; T LYMPHOCYTE RECEPTOR; TASOCITINIB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

ANTIGEN SPECIFICITY; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; DENDRITIC CELL; DERMATOMYOSITIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; GENETIC VARIABILITY; GRAFT REJECTION; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LOW DRUG DOSE; MICROENVIRONMENT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TISSUE INJURY; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES;

EID: 79955623932     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.36     Document Type: Review

References (96)

1. Alivernini, S., Laria, A., Gremese, E., Zoli, A. & Ferraccioli, G. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res. Ther. 11, R163 (2009).
2. Nam, J. L. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 69, 976-986 (2010).
3. Scott, D. L., Wolfe, F. & Huizinga, T. W. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010).
4. Takeuchi, T. & Kameda, H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 6, 644-652 (2010).
5. Marti, L. et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann. NY Acad. Sci. 1173, 334-342 (2009).
6. van Vollenhoven, R. F. New and future agents in the treatment of rheumatoid arthritis. Discov. Med. 9, 319-327 (2010).
7. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994). (Pubitemid 24140436)
8. Steinman, R. M. & Mellman, I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 305, 197-200 (2004). (Pubitemid 38886724)
9. Steinman, L. Immune therapy for autoimmune diseases. Science 305, 212-216 (2004). (Pubitemid 38886728)
10. Kronenberg, M. & Rudensky, A. Regulation of immunity by self-reactive T cells. Nature 435, 598-604 (2005). (Pubitemid 40825499)
11. Laganà, B., Vinciguerra, M. & D'Amelio, R. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept. Clin. Drug Investig. 29, 185-202 (2009).
12. Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613-620 (2006). (Pubitemid 43228639)
13. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003). (Pubitemid 37409707)
14. Matsumoto, I. et al. Therapeutic effects of antibodies to tumor necrosis factor-á, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res. Ther. 10, R66 (2008).
15. Platt, A. M. et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J. Immunol. 185, 1558-1567 (2010).
16. Bluestone, J. A. et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8, 2086-2096 (2008).
17. Dörner, T., Kinnman, N. & Tak, P. P. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther. 125, 464-475 (2010).
18. Edwards, J. C. & Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6, 394-403 (2006).
19. DiLillo, D. J., Horikawa, M. & Tedder, T. F. B-lymphocyte effector functions in health and disease. Immunol. Res. doi:10.1007/s12026-010-8189-8183.
20. DiLillo, D. J., Matsushita, T. & Tedder, T. F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. NY Acad. Sci. 1183, 38-57 (2010).
21. Sellam, J. et al. B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.30233.
22. Moura, R. A. et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 50, 278-282 (2011).
23. Townsend, M. J., Monroe, J. G. & Chan, A. C. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol. Rev. 237, 264-283 (2010).
24. Sutherland, A. P., Mackay, F. & Mackay, C. R. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol. Ther. 112, 774-786 (2006). (Pubitemid 44604415)
25. Tak, P. P. et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58, 61-72 (2008).
26. Bracewell, C., Isaacs, J. D., Emery, P. & Ng, W. F. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 9, 909-919 (2009).
27. Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723-732 (2006).
28. Opar, A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat. Rev. Drug Discov. 9, 257-258 (2010).
29. Lindstrom, T. M. & Robinson, W. H. A multitude of kinases-which are the best targets in treating rheumatoid arthritis? Rheum. Dis. Clin. North Am. 36, 367-383 (2010).
30. Page, T. H., Brown, A., Timms, E. M., Foxwell, B. M. & Ray, K. P. Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo? Arthritis Rheum. 62, 3221-3231 (2010).
31. Riese, R. J., Krishnaswami, S. & Kremer, J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatol. 24, 513-526 (2010).
32. Hammaker, D. & Firestein G. S. "Go upstream, young man": lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (Suppl. 1), i77-i82 (2010).
33. Genovese, M. C. et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63, 337-345 (2011).
34. Fleischmann, R. et al. Phase 3 study of oral JAK inhibitor tasocitinib (CP-690, 550) monotherapy in patients with active rheumatoid arthritis. Presented at the 74th Annual Scientific Meeting of the American College of Rheumatology.
35. Williams, W. V. et al. Initial efficacy of INCB018424, a selective Janus kinase1 & 2 (JAK1 & 2) inhibitor in rheumatoid arthritis (RA). Presented at EULAR 2008, Annual Scientific Congress.
36. Damjanov, N., Kauffman, R. S. & Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232-1241 (2009).
37. Dougados, M. et al. Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. Clin. Exp. Rheumatol. 28, 259-260 (2010).
38. Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578-582 (2009).
39. Ehrenstein, M. R. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFá therapy. J. Exp. Med. 200, 277-285 (2004). (Pubitemid 39031247)
40. Chiu, W. C., Lai, Y. P. & Chou, M. Y. Humanization and characterization of an anti-human TNF-á murine monoclonal antibody. PLoS ONE 6, e16373 (2011).
41. Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898 (2009).
42. Moran, E. M. et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-á, Oncostatin M and response to biologic therapies. Arthritis Res. Ther. 11, R113 (2009).
43. Aerts, N. E. et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 49, 2264-2272 (2010).
44. Febbraio, M. A., Rose-John, S. & Pedersen, B. K. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin. Pharmacol. Ther. 87, 396-398 (2010).
45. Yoshida, H., Hashizume, M., Suzuki, M. & Mihara, M. Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur. J. Pharmacol. 634, 178-183 (2010).
46. An, M. M. et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 66, 49-59 (2010).
47. Moots, R. J., Ostör, A. J. & Isaacs, J. D. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? Expert Opin. Investig. Drugs 18, 1687-1699 (2009).
48. Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69, 88-96 (2010).
49. Singh, J. A., Beg, S. & Lopez-Olivo, M. A. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD008331. doi:10.1002/14651858.CD008331.pub2 (2010).
50. Feist, E. & Burmester, G. R. Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? Nat. Clin. Pract. Rheumatol. 5, 128-129 (2009).
51. Safety, tolerability and efficacy of ACZ885 (canakinumab) in patients with active rheumatoid arthritis identifier: NCT00784628. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00784628 (2010).
52. Genovese, M. et al. Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment: results of a phase IIb study. Presented at the 74th Annual Scientific Meeting of the American College of Rheumatology.
53. Wulffraat, N. M. & Kuis, W. Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis? Rheumatology (Oxford) 38, 764-766 (1999). (Pubitemid 29507399)
54. de Kleer, I. M. et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann. Rheum. Dis. 63, 1318-1326 (2004). (Pubitemid 39273515)
55. Wulffraat, N. M. et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity 41, 632-638 (2008).
56. de Kleer, I. et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood 107, 1696-1702 (2006). (Pubitemid 43242411)
57. Albani, S. & Prakken, B. T cell epitope-specific immune therapy for rheumatic diseases. Arthritis Rheum. 54, 19-25 (2006). (Pubitemid 43122182)
58. Lanzavecchia, A. & Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 106, 263-266 (2001). (Pubitemid 32772609)
59. Sallusto, F. & Lanzavecchia, A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 4 (Suppl. 3), S127-S132 (2002).
60. Banchereau, J., Pulendran, B., Steinman, R. & Palucka, K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J. Exp. Med. 192, F39-F44 (2000). (Pubitemid 32049761)
61. Steinman, R. M. & Nussenzweig, M. C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl Acad. Sci. USA 99, 351-358 (2002). (Pubitemid 34060366)
62. Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003). (Pubitemid 37174545)
63. Hackstein, H. & Thomson, A. W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4, 24-34 (2004). (Pubitemid 38084129)
64. Kleijwegt, F. S. et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J. Immunol. 185, 1412-1418 (2010).
65. Harry, R. A., Anderson, A. E., Isaacs, J. D. & Hilkens, C. M. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 69, 2042-2050 (2010).
66. Racke, M. K., Lovett-Racke, A. E. & Karandikar, N. J. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74 (Suppl. 1), S25-S30 (2010).
67. Liblau, R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J. Neurol. Sci. 287 (Suppl. 1), S17-S23 (2009).
68. Weiner, H. L. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J. Clin. Invest. 106, 935-937 (2000).
69. Bluestone, J. A. Regulatory T cells: therapeutic potential for treating transplant rejection and type I diabetes. J. Vis. Exp. 7, 257 (2007).
70. Mayer, L. Current advances in gastrointestinal immunology. Mt Sinai J. Med. 60, 178-179 (1993).
71. Joosten, L. A. et al. Induction of tolerance with intranasal administration of human cartilage gp-39 in DBA/1 mice: amelioration of clinical, histologic, and radiologic signs of type II collagen-induced arthritis. Arthritis Rheum. 43, 645-655 (2000). (Pubitemid 30394957)
72. Thompson, H. S. & Staines, N. A. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. 64, 581-586 (1986). (Pubitemid 16122396)
73. Trentham, D. E., Townes, A. S. & Kang, A. H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146, 857-868 (1977). (Pubitemid 8175993)
74. Staines, N. A. et al. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103, 368-375 (1996). (Pubitemid 26089942)
75. Cope, A. P. et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Arthritis Rheum. 42, 1497-1507 (1999). (Pubitemid 30265609)
76. Kim, W. U. et al. Type II collagen autoimmunity in rheumatoid arthritis. Am. J. Med. Sci. 327, 202-211 (2004).
77. Trentham, D. E. et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261, 1727-1730 (1993). (Pubitemid 23332920)
78. Choy, E. H. et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44, 1993-1997 (2001). (Pubitemid 33644040)
79. Sieper, J. et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 39, 41-51 (1996).
80. Barnett, M. L. et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 41, 290-297 (1998). (Pubitemid 28087697)
81. Kavanaugh, A. et al. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J. Rheumatol. 30, 449-454 (2003). (Pubitemid 36301932)
82. Barnett, M. L., Combitchi, D. & Trentham, D. E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 39, 623-628 (1996). (Pubitemid 26118041)
83. Myers, L. K. et al. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. 44, 1775-1781 (2001). (Pubitemid 32758223)
84. Koffeman, E. C. et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 60, 3207-3216 (2009).
85. Pockley, A. G. Heat shock proteins in health and disease: therapeutic targets or therapeutic agents? Expert Rev. Mol. Med. 3, 1-21 (2001).
86. Roord, S. T. et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 1, e87 (2006).
87. de Jong, H. et al. Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis. Arthritis Rheum. 60, 1966-1976 (2009).
88. Massa, M. et al. Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum. 56, 1648-1657 (2007). (Pubitemid 46764094)
89. Kamphuis, S. et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 366, 50-56 (2005). (Pubitemid 40956530)
90. La Cava, A. et al. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. J. Clin. Invest. 100, 658-663 (1997). (Pubitemid 27340514)
91. Albani, S. & Carson, D. A. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunol. Today 17, 466-470 (1996).
92. Albani, S. et al. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat. Med. 1, 448-452 (1995).
93. Albani, S., Tuckwell, J. E., Esparza, L., Carson, D. A. & Roudier, J. The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J. Clin. Invest. 89, 327-331 (1992).
94. Prakken, B. J. et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 101, 4228-4233 (2004). (Pubitemid 38405911)
95. Quintana, F. J. & Cohen, I. R. The HSP60 immune system network. Trends Immunol. 32, 89-95 (2011).
96. Klarenbeek, N. B. et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann. Rheum. Dis. 70, 315-319 (2011).